Skip to main content
Top
Published in: Journal of Cancer Survivorship 2/2013

01-06-2013

Time away from work: employed husbands of women treated for breast cancer

Authors: Cathy J. Bradley, Bassam Dahman

Published in: Journal of Cancer Survivorship | Issue 2/2013

Login to get access

Abstract

Purpose

We estimated the effect of cancer and its treatment on employment and weekly hours worked for employed men whose wives were newly diagnosed with breast cancer.

Methods

We collected employment data on 373 married, insured, and employed men from 2007 to 2011. The outcomes were employment, any decrease in weekly hours worked, and change in weekly hours worked from pre-diagnosis to 2 and 9 months following treatment initiation relative to a non-cancer control group (N = 451 for the 2-month survey and N = 328 for the 9-month survey) extracted from the Current Population Survey. We also stratified the cancer sample by those undergoing chemotherapy and radiation treatment at the time of the interviews and repeated the analysis.

Results

Men whose wives were newly diagnosed with cancer were more likely to decrease weekly hours worked (p < 0.05) 2 months following treatment initiation than men in the control group. However, the change in weekly hours worked was not statistically significantly different from the change experienced by men in the control group. No differences between the two groups were observed at the 9-month interview.

Conclusions

Breast cancer treatment had a small, negative effect on work outcomes in employed husbands of affected women.

Implications for cancer survivors

While the results were generally favorable, more research is needed to understand the extent to which caregiving needs are met in an employed cancer population.
Footnotes
1
We tested several matching methods including nearest neighbor, 1-to-1 matching with replacement, kernel matching with bootstrap standard errors, local linear regression, and spline matching. These methods yielded comparable results. We use the kernel method where all cancer subjects are matched with a weighted average of all controls with weights that are inversely proportional to the distance between the propensity scores of the cancer and control observations. For a review of matching methods, see Becker and Ichino [13] and Smith and Todd [14].
 
Literature
2.
go back to reference Petrie W, Logan J, DeGrasse C. Research review of the supportive care needs of spouses of women with breast cancer. Oncol Nurs Forum. 2001;28(10):1601–7.PubMed Petrie W, Logan J, DeGrasse C. Research review of the supportive care needs of spouses of women with breast cancer. Oncol Nurs Forum. 2001;28(10):1601–7.PubMed
5.
go back to reference Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ. 2004;170(12):1795–801.PubMed Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ. 2004;170(12):1795–801.PubMed
6.
go back to reference Yabroff KR, Kim Y. Time costs associated with informal caregiving for cancer survivors. Cancer. 2009;115(18 Suppl):4362–73.PubMedCrossRef Yabroff KR, Kim Y. Time costs associated with informal caregiving for cancer survivors. Cancer. 2009;115(18 Suppl):4362–73.PubMedCrossRef
7.
go back to reference Bradley C, Neumark D, Luo Z, et al. Employment-based health insurance, illness, and labor supply of women: evidence from married women with breast cancer. Health Econ. 2006;16(7):719–34.CrossRef Bradley C, Neumark D, Luo Z, et al. Employment-based health insurance, illness, and labor supply of women: evidence from married women with breast cancer. Health Econ. 2006;16(7):719–34.CrossRef
8.
go back to reference Hollenbeak CS, Short PF, Moran J. The implications of cancer survivorship for spousal employment. J Cancer Surviv. 2011;5(3):226–34.PubMedCrossRef Hollenbeak CS, Short PF, Moran J. The implications of cancer survivorship for spousal employment. J Cancer Surviv. 2011;5(3):226–34.PubMedCrossRef
12.
go back to reference Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.CrossRef Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.CrossRef
13.
go back to reference Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J. 2002;2(2):358–77. Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J. 2002;2(2):358–77.
14.
go back to reference Smith J, Todd P. Does matching overcome Lalonde’s critique of nonexperimental estimators? J Econ. 2005;125(1–2):305–53. Smith J, Todd P. Does matching overcome Lalonde’s critique of nonexperimental estimators? J Econ. 2005;125(1–2):305–53.
15.
go back to reference Lopez V, Copp G, Molassiotis A. Male caregivers of patients with breast and gynecologic cancer: experiences from caring for their spouses and partners. Cancer Nurs. 2012;35(6):402–10.PubMedCrossRef Lopez V, Copp G, Molassiotis A. Male caregivers of patients with breast and gynecologic cancer: experiences from caring for their spouses and partners. Cancer Nurs. 2012;35(6):402–10.PubMedCrossRef
Metadata
Title
Time away from work: employed husbands of women treated for breast cancer
Authors
Cathy J. Bradley
Bassam Dahman
Publication date
01-06-2013
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 2/2013
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-012-0263-5

Other articles of this Issue 2/2013

Journal of Cancer Survivorship 2/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine